前瞻性随机双盲安慰剂对照评价重组抗凝血酶对比安慰剂在早产子痫前期中的药代动力学、安全性和有效性
这项在23家医院开展的双盲安慰剂对照试验随机纳入120例孕23 0/7至30 0/7周、计划期待治疗的早产子痫前期单胎孕妇,比较静脉重组人抗凝血酶与安慰剂。两组从随机到分娩增加的中位天数无差异(5.0天 vs 6.0天,P=.95),新生儿复合发病率评分及母体并发症亦无差异,未发现与重组人抗凝血酶相关的安全性问题。结论为重组人抗凝血酶既未延长妊娠,也未改善母儿结局。
要点
- 重组人抗凝血酶组与安慰剂组从随机到分娩的中位增加天数无差异(5.0天 vs 6.0天,P=.95)。
- 两组新生儿复合发病率评分及母体并发症均无差异。
- 尽管达到超生理抗凝血酶浓度,未发现与重组人抗凝血酶相关的安全性问题。
核心结论
- 在早产子痫前期中给予重组人抗凝血酶既未延长妊娠,也未改善新生儿或母体结局。
研究设计与样本
- 在23家医院开展的双盲、安慰剂对照试验,共随机纳入120例孕妇。
- 纳入标准为单胎妊娠、孕23 0/7至30 0/7周早发型或叠加型子痫前期且计划期待治疗。
- 在标准治疗基础上,随机接受重组人抗凝血酶250 mg负荷剂量后以2000 mg/24小时持续输注至分娩,或接受相同生理盐水输注。
- 主要结局为从随机到分娩增加的天数,次要结局为新生儿复合发病率评分。
主要发现
- 入组时中位孕周两组无差异:重组人抗凝血酶组27.3周(范围23.1-30.0),安慰剂组27.6周(范围23.0-30.0),P=.67。
- 从随机到分娩的中位增加天数两组无差异:重组人抗凝血酶组5.0天(范围0-75),安慰剂组6.0天(范围0-85),P=.95。
- 两组新生儿复合发病率评分及母体并发症均无差异。
- 尽管达到超生理抗凝血酶浓度,本研究未发现与重组人抗凝血酶相关的安全性问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite expectant management, preeclampsia remote from term usually results in preterm delivery. Antithrombin, which displays antiinflammatory and anticoagulant properties, may have a therapeutic role in treating preterm preeclampsia, a disorder characterized by endothelial dysfunction, inflammation, and activation of the coagulation system. OBJECTIVE: This randomized, placebo-controlled clinical trial aimed to evaluate whether intravenous recombinant human antithrombin could prolong gestation and therefore improve maternal and fetal outcomes. STUDY DESIGN: We performed a double-blind, placebo-controlled trial at 23 hospitals. Women were eligible if they had a singleton pregnancy, early-onset or superimposed preeclampsia at 23 0/7 to 30 0/7 weeks' gestation, and planned expectant management. In addition to standard therapy, patients were randomized to receive either recombinant human antithrombin 250 mg loading dose followed by a continuous infusion of 2000 mg per 24 hours or an identical saline infusion until delivery. The primary outcome was days gained from randomization until delivery. The secondary outcome was composite neonatal morbidity score. A total of 120 women were randomized. RESULTS: There was no difference in median gestational age at enrollment (27.3 weeks' gestation for the recombinant human antithrombin group [range, 23.1-30.0] and 27.6 weeks' gestation for the placebo group [range, 23.0-30.0]; P=.67). There were no differences in median increase in days gained (5.0 in the recombinant human antithrombin group [range, 0-75] and 6.0 for the placebo group [range, 0-85]; P=.95). There were no differences between groups in composite neonatal morbidity scores or in maternal complications. No safety issues related to recombinant human antithrombin were noted in this study, despite the achievement of supraphysiological antithrombin concentrations. CONCLUSION: The administration of recombinant human antithrombin in preterm preeclampsia neither prolonged pregnancy nor improved neonatal or maternal outcomes.
引用
- Paidas MJ, Tita ATN, Macones GA, et al. Prospective, randomized, double-blind, placebo-controlled evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia. Am J Obstet Gynecol. 2020. PMID: 32780999. doi:10.1016/j.ajog.2020.08.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。